iv inducing agents
iv inducing agents
Agents
Physical properties
Pharmacodynamics properties
• High therapeutic ratio
•Minimal cardiovascular and respiratory effects
•No histamine release/hypersensitivity reactions
• No emetic effects
• No involuntary movements
•No emergence nightmares
•No hang over effect
•No adrenocortical suppression
• Safe to use in porphyria
Drug
s
BARBITURATES
PROPOFOL
KETAMINE
ETOMIDATE
BENZODIAZEPINE
OPIOIDS
BARBITURAT
ES
e.g.
• Thiopental
• Thiamylal
• Pentobarbital
• Secobarbital
• Methohexital
Mechanisms of Action
• Depress the reticular activating
• Suppress transmission of excitatory neurotransmitters
(acetylcholine)
• Enhance transmission of inhibitory neurotransmitters
(GABA)
BARBITURAT
ES
Structure
Pharmacokinetics
• BIOTRANSFORMATION
• Hepatic oxidation to inactive water-soluble metabolites.
• EXCRETION
• Renal excretion
• Important for less protein-bound and less lipid-soluble agents such as
phenobarbital,
• Water-soluble end products of hepatic biotransformation.
BARBITURATES
RESPIRATORY
• Ventilatory response to hypercapnia and hypoxia ---Decreases
• Tidal volume --- decreased
• Respiratory rate --- decreased
• Cerebral
• Cerebral blood flow --- Decrease
• Intracranial pressure---Decrease
• Cerebral perfusion pressure--- Increased
• (CPP equals cerebral artery pressure minus cerebral venous pressure or
intracranial pressure.)
• Cerebral oxygen consumption --- Decrease
• RENAL
• Reduce renal blood flow and glomerular filtration rate in proportion
to the fall in blood pressure.
• HEPATIC
• Hepatic blood flow is decreased.
• Induction of hepatic enzymes increases the rate of metabolism of
some drugs
• The induction of aminolevulinic acid synthetase stimulates the formation of
porphyrin (an intermediary in heme synthesis), which may precipitate acute
intermittent porphyria or variegate porphyria in susceptible individuals.
• IMMUNOLOGICAL
• Sulfur-containing thiobarbiturates evoke mast cell histamine release
in vitro, whereas oxybarbiturates do not.
BARBITURATES
Specific complication :
Intra-arterial Injection
• Immediate, intense vasoconstriction and excruciating pain that radiates
along the distribution of the artery.
• Severe Vasoconstriction may obscure distal arterial pulses.
• Gangrene and permanent nerve damage may occur.
BARBITURATES
Mechanism of Damage
• Due to be the precipitation of thiopental crystals inflammatory
response and arteriti s microembolization that follows, eventually
results in occlusion of the distal circulation.
Treatment
• Immediate attempts to dilute the drug --- injection of saline
• Prevention of arterial spasm & sustain adequate blood flow—
• lidocaine, papaverine, or phenoxybenzamine
• stellate ganglion block or brachial plexus block
Propofo
l
• Structure
• Propofol (2,6-diisopropylphenol)
• Propofol is not water soluble
• 1% solution (10 mg/mL) --- an oil-in-water emulsion
Containing
• soybean oil
• glycerol
• egg lecithin
• Mechanisms of Action
• Facilitation of inhibitory neurotransmission mediated by
GABA.
Propof
ol
Pharmacokinetics
• DISTRIBUTION
• High lipid solubility
• onset of action that is almost as rapid as that of thiopental (one-arm-to-brain
circulation time).
• Awakening from a single bolus dose is also rapid due to a very short initial
distribution half-life (2–8 min).
• Recovery --- rapid
• Hangover --- less
• This makes it a good agent for outpatient anesthesia.
• BIOTRANSFORMATION
• Hepatic and extra hepatic metabolism
• EXCRETION
• Primarily excreted in the urine
• chronic renal failure does not affect clearance of the parent
drug.
Propof
ol
Effects on organ
CARDIOVASCULAR
• Blood pressure ---decrease due to a
• Fall in systemic vascular resistance
• Hypotension is more pronounced than with thiopental.
• HR: No change /Bradycardia
RESPIRATORY
• Profound respiratory depressant following an induction dose---apnea
• Inhibits hypoxic ventilatory drive and depresses the normal response to
hypercarbia.
• Depression of upper airway reflexes
• Helpful during intubation or laryngeal mask placement in the absence of
paralysis.
• Lower incidence of wheezing
• Safe in asthmatic patients.
Propofol
CEREBRAL
• Cerebral blood flow---- decreases
• Intracranial pressure---- decreases.
• Antiemetic effects
• preferred drug for outpatient anesthesia.
• Anticonvulsant properties (ie burst suppression)
• used to terminate status epilepticus.
• Safely administered to epileptic patients.
• Intraocular pressure----Decreases
Propof
ol
Use :
• Induction of Anesthesia 1.5 to 2.5 mg/kg
• Intravenous Sedation 25 to 100 µg/kg per minute IV
• Maintenance of Anesthesia 100 to 300 µg/kg per minute IV
• Nonhypnotic Therapeutic Applications
• Antiemetic Effects
• Mech –unknown
• 10 to 15 mg IV
• Anticonvulsant Activity
• Attenuation of Bronchoconstriction
Propofol
Specific complication
• Bacterial Growth
• Supports the growth of Escherichia coli and Pseudomonas aeruginosa.
• Recommendation:
• An aseptic technique be used in handling propofol, as reflected by disinfecting
the ampule neck surface or vial rubber stopper with 70% isopropyl alcohol.
• The contents of the ampule containing propofol should be withdrawn into a
sterile syringe immediately after opening and administered promptly.
• The contents of an opened ampule must be discarded if they are not used within
6 hours. In the ICU, the tubing and any unused portion of propofol must be
discarded after 12 hours.
KETAMINE
Mechanisms of Action
• N-methyl-D-aspartate receptor antagonist.
• Produce dissociative Anaesthesia
Structure :
• structural analogue of phencyclidine
KETAMINE
Pharmacokinetics
• ABSORPTION
• Intravenously or intramuscularly
• Peak plasma levels are usually achieved within 10–15 min after
intramuscular injection.
• DISTRIBUTION
• Ketamine is more lipid soluble and less protein bound than
thiopental
• Half-life is 10–15 min
• Awakening is due to redistribution to peripheral
compartments.
• BIOTRANSFORMATION
• Liver to several metabolites (eg, norketamine)
• EXCRETION
• End products of biotransformation are excreted renally
KETAMIN
E
Uses
• Induction of Anesthesia
• Intravenous ketamine, 1 to 2 mg/kg
• Intramuscular administration of 4 to 8 mg/kg.
• Analgesia
• Subanesthetic doses of ketamine, 0.2 to 0.5 mg/kg IV.
• Neuraxial Analgesia
• Limited value.
KETAMIN
E
Effects on organ system
Central Nervous System
• cerebral blood flow --- Increase
• CMRO2---Increase
• Intracranial Pressure--- Increase
Cardiovascular System
• Sympathetic nervous system stimulation
• Systemic and pulmonary arterial blood pressure---- increased
• Heart rate ---- increased
• Cardiac output---- increased
• Myocardial oxygen requirements ---- increased
KETAMIN
E
• But in Critically ill patients
• Unexpected decreases in systemic blood pressure and cardiac output, which
may reflect a depletion of endogenous catecholamine stores and exhaustion
of sympathetic nervous system compensatory mechanisms.
• Unmasking of ketamine's direct myocardial depressant effects.
Ventilation and Airway
• Depression of ventilation: not significant
• Upper airway skeletal muscle tone :maintained,
• Upper airway reflexes : intact
• Salivary and tracheobronchial mucous gland: Increased secretions are
increased
• Use antisialagogue before ketamine
• Bronchodilatory effects
• Drug of choice for induction patients with asthma
KETAMINE
Specific Complications
Emergence Delirium (Psychedelic Effects)
• In postoperative period visual, auditory, proprioceptive, and
confusional illusions, which may progress to delirium.
• Dreams and hallucinations can occur up to 24 hours after the
administration of ketamine.
• Mechanisms
• Emergence delirium probably occurs secondary to ketamine-
induced depression of the inferior colliculus and medial
geniculate nucleus, thus leading to the misinterpretation of
auditory and visual stimuli.
KETAMIN
E
• Structure
• Carboxylated imidazole-containing compound
• Commercial Preparation
• Etomidate is prepared as a fat emulsion, and pain on injection and venous
irritation is unlikely.
• Mechanism of Action
• GABA receptors
ETOMIDAT
E
Uses
• Etomidate (0.2 to 0.4 mg/kg IV)
• As an alternative to propofol or barbiturates for the induction of
anesthesia, especially in the presence of an unstable cardiovascular
system.
ETOMIDATE
MECHANISM OF ACTION
• Facilitating the actions of γ-aminobutyric acid (GABA), the
principal inhibitory neurotransmitter in the CNS
RESPIRATORY
•Depress the ventilatory response to CO
2
CEREBRAL
Mechanisms of Action
• Opioids bind to specific receptors located throughout the central
nervous system and other tissues.
• Four major types of opioid receptor
•µ
•Κ
•σ
•δ
CEREBRAL
• GASTROINTESTINAL
• slow gastric emptying time by reducing peristalsis.
• Biliary colic may result from opioid-induced contraction of the
sphincter of Oddi.
• ENDOCRINE
• Stress response to surgical stimulation ---decresed
• Ischemic heart disease patients may benefit from attenuation of the
stress response .
Thank You